Rember’s Early Success

The drug called Rember (methylthioninium chloride) is receiving substantial press in the news and medical world for its success in slowing the progress of mental deterioration associated with Alzheimer’s disease. The Alzheimer’s drugs currently available {Aricept, Exelon, Razadyne (previously Reminyl), Cognex, and Namenda} have been said to only ease the symptoms of the mind-robbing disease.

Developed by Singapore-based TauRx Therapeutics, Rember is an experimental drug that takes a new approach to treating the disease by targeting the build up of a specific protein in the brain called Tau. Tau causes tangles that accumulate inside memory cells, and destroys them during the process. Rember is designed to target these Tau tangles, therefore leading to positive results for reducing mental decline.

If clinical trials continue to be successful and sustainable, this is ground-breaking news for the medical industry and for individuals battling with this debilitating disease. The name itself is memorable (no pun intended), straightforward and distinctive. In today’s regulatory environment, getting a name like this approved signifies a major homerun for the company.